The purpose of this trial is to learn about the effects of inclisiran in people with serious heart conditions (acute coronary syndromes), when this treatment is started early after hospital admission. To do this, researchers will test the effects of inclisiran compared to placebo, when given with standard treatment.
Signed informed consent must be obtained prior to participation in the study.
Males and females, ≥18 years of age at the time of providing written informed consent.
Ability to understand study's requirements and provide informed consent and comply with all required study procedures.
Hospitalization for a ACS event (STEMI or NSTEMI).
Hemodynamic instability: hypotension, defined as sustained systolic blood pressure of <90 mmHg due to cardiac failure with associated symptoms requiring inotropes
Arrhythmic events: Ventricular storm (e.g., torsade, ventricular tachycardia, ventricular flutter)
Cardiogenic shock or mechanical complication of myocardial infarction
New York Heart Association (NYHA) class IV heart failure